ID   MX-1
AC   CVCL_4774
SY   MX1; MXI
DR   BTO; BTO:0004179
DR   CLO; CLO_0009915
DR   EFO; EFO_0006457
DR   ArrayExpress; E-MTAB-2706
DR   BioSample; SAMN03472921
DR   ChEMBL-Cells; CHEMBL3308046
DR   ChEMBL-Targets; CHEMBL613704
DR   CLS; 300296
DR   DepMap; ACH-002328
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001002554
DR   GEO; GSM845398
DR   GEO; GSM844612
DR   GEO; GSM844611
DR   GEO; GSM844613
DR   GEO; GSM1172987
DR   GEO; GSM1172893
DR   LINCS_HMS; 51090
DR   LINCS_LDP; LCL-2072
DR   NCI-DTP; MX-1
DR   PharmacoDB; MX1_973_2019
DR   PubChem_Cell_line; CVCL_4774
DR   Wikidata; Q54907134
RX   PubMed=10969801;
RX   PubMed=24176112;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25960936;
RX   PubMed=26589293;
RX   PubMed=29045385;
WW   https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: JWGray breast cancer cell line panel.
CC   Population: Caucasian.
CC   Characteristics: Established from a tumor xenograft established in atyhmic mice.
CC   Doubling time: 30-35 hours (CLS=300296); 113.83 hours (JWGray panel).
CC   HLA typing: A*11:01,74:01; B*15:03,35:01; C*02:02,04:01; DQB1*03:09,05:01; DRB1*01:03,11:08 (PubMed=25960936).
CC   HLA typing: A*11:01,74:01; B*15:03,35:01; C*02:02,04:01; DRB1*01:03,01:03 (PubMed=26589293).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln52Valfs*3 (c.154_158delCAATG); Zygosity=Unspecified (PubMed=29045385).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Breast; UBERON=UBERON_0000310.
ST   Source(s): CLS=300296; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 11 (PubMed=25877200)
ST   D13S317: 11,12 (CLS=300296)
ST   D16S539: 12
ST   D18S51: 12,16
ST   D19S433: 13,15.2,16.2
ST   D21S11: 29,30,31,32 (CLS=300296)
ST   D21S11: 29,32 (PubMed=25877200)
ST   D2S1338: 19
ST   D3S1358: 15
ST   D5S818: 12
ST   D7S820: 11 (PubMed=25877200)
ST   D7S820: 11,12 (CLS=300296)
ST   D8S1179: 11 (PubMed=25877200)
ST   D8S1179: 11,12,13 (CLS=300296)
ST   FGA: 20
ST   Penta D: 6,9,11
ST   Penta E: 14
ST   TH01: 7,9
ST   TPOX: 7,8 (CLS=300296)
ST   TPOX: 8 (PubMed=25877200)
ST   vWA: 17 (PubMed=25877200)
ST   vWA: 17,18 (CLS=300296)
DI   NCIt; C4872; Breast carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   29Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 27
//
RX   PubMed=10969801;
RA   Forozan F., Mahlamaki E.H., Monni O., Chen Y.-D., Veldman R., Jiang Y.,
RA   Gooden G.C., Ethier S.P., Kallioniemi A., Kallioniemi O.-P.;
RT   "Comparative genomic hybridization analysis of 38 breast cancer cell
RT   lines: a basis for interpreting complementary DNA microarray data.";
RL   Cancer Res. 60:4519-4525(2000).
//
RX   PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110;
RA   Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M.,
RA   Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S.,
RA   Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S.,
RA   Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J.,
RA   Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.;
RT   "Modeling precision treatment of breast cancer.";
RL   Genome Biol. 14:R110.1-R110.14(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=29045385; DOI=10.1038/nature24006;
RA   Kategaya L., Di Lello P., Rouge L., Pastor R., Clark K.R.,
RA   Drummond J., Kleinheinz T., Lin E., Upton J.-P., Prakash S.,
RA   Heideker J., McCleland M.L., Ritorto M.S., Alessi D.R., Trost M.,
RA   Bainbridge T.W., Kwok M.C.M., Ma T.P., Stiffler Z., Brasher B.,
RA   Tang Y.-Y., Jaishankar P., Hearn B.R., Renslo A.R., Arkin M.R.,
RA   Cohen F., Yu K.-B., Peale F.V., Gnad F., Chang M.T., Klijn C.,
RA   Blackwood E., Martin S.E., Forrest W.F., Ernst J.A., Ndubaku C.,
RA   Wang X.-J., Beresini M.H., Tsui V., Schwerdtfeger C., Blake R.A.,
RA   Murray J., Maurer T., Wertz I.E.;
RT   "USP7 small-molecule inhibitors interfere with ubiquitin binding.";
RL   Nature 550:534-538(2017).
//